Research programme: SDX 101 second generation analogues - Salmedix
Latest Information Update: 30 May 2007
At a glance
- Originator Salmedix
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 May 2007 Discontinued - Preclinical for Cancer in USA (PO)
- 16 Jun 2005 Salmedix has been acquired by Cephalon
- 20 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the adverse events and Cancer pharmacodynamics sections